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Abstract
Several epidemiological studies have correlated the use of non-steroidal anti-inflammatory drugs (NSAID) with reduced risk
of ovarian cancer, the most lethal gynecological cancer, diagnosed usually in late stages of the disease. We have previously
established that the pro-apoptotic cytokine melanoma differentiation associated gene-7/Interleukin-24 (mda-7/IL-24) is a
crucial mediator of NSAID-induced apoptosis in prostate, breast, renal and stomach cancer cells. In this report we evaluated
various structurally different NSAIDs for their efficacies to induce apoptosis and mda-7/IL-24 expression in ovarian cancer
cells. While several NSAIDs induced apoptosis, Sulindac Sulfide and Diclofenac most potently induced apoptosis and
reduced tumor growth. A combination of these agents results in a synergistic effect. Furthermore, mda-7/IL-24 induction by
NSAIDs is essential for programmed cell death, since inhibition ofmda-7/IL-24 by small interfering RNA abrogates apoptosis.
mda-7/IL-24 activation leads to upregulation of growth arrest and DNA damage inducible (GADD) 45 a and c and JNK
activation. The NF-kB family of transcription factors has been implicated in ovarian cancer development. We previously
established NF-kB/IkB signaling as an essential step for cell survival in cancer cells and hypothesized that targeting NF-kB
could potentiate NSAID-mediated apoptosis induction in ovarian cancer cells. Indeed, combining NSAID treatment with NF-
kB inhibitors led to enhanced apoptosis induction. Our results indicate that inhibition of NF-kB in combination with
activation of mda-7/IL-24 expression may lead to a new combinatorial therapy for ovarian cancer.
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Introduction
Ovarian cancer represents the most lethal gynecological cancer
and the 5th leading cause of women death related to cancer in the
United States [1]. Late diagnosis is one of the main hurdles to treat
ovarian cancer, as nearly 70% of women present with an
advanced stage of the disease at diagnosis [2]. Several epidemi-
ological studies have suggested that the use of NSAIDs at clinically
relevant concentrations reduces colorectal [3], breast [4] and
ovarian cancer risks [5,6,7], although controversy still remains
[8,9]. One major target of NSAID action is inhibition of
cyclooxygenase (COX), which are responsible for the conversion
of arachidonic acids into prostaglandins and employ a variety of
different mechanisms. The two COX genes, COX-1 and COX-2,
are almost identical; however, one relevant difference is that
COX-1 expression is constitutive, whereas COX-2 expression is
induced by growth factors and pro-inflammatory stimuli [10].
NSAIDs are typically classified as specific COX-2 inhibitors or
non-specific COX inhibitors. In ovarian cancer COX-1, but not
COX-2 has been found to be overexpressed [11,12], nevertheless
other studies reported that COX-2 is also upregulated [13,14].
High COX-1 expression in ovarian cancer strongly correlates with
high levels of Vascular Endothelial Growth Factor (VEGF)
[15,16,17] and NSAIDs inhibit VEGF production in ovarian
cancer cell lines [12,18] indicating that COX-1 may regulate
VEGF expression. Angiogenesis and VEGF expression are
implicated in ascites formation [19] and metastasis of ovarian
cancer [20], while its inhibition prevents ascites formation and
inhibits disseminated cancer growth [21].
Our previous study demonstrates that NSAIDs also induce
apoptosis of cancer cells via induction of mda-7/IL-24 expression
[22], leading to enhanced expression of two members of the
Growth Arrest and DNA-Damage 45 (GADD45) family [23]. The
GADD45 gene family encodes three structurally highly related
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growth arrest- and DNA damage-inducible proteins, GADD45 a,
b and c play a role in the G2/M checkpoint in response to DNA
damage [24]. Under normal physiological conditions, mda-7/IL-
24 is expressed in cells of the immune system and normal
melanocytes [25]. High levels of mda-7/IL-24 have been
demonstrated to specifically induce apoptosis of cancer cells and
therefore mda-7/IL-24 has been referred as a ‘‘magic bullet’’
[26,27]. Moreover, several studies indicated that overexpression of
mda-7/IL-24 by a recombinant adenovirus results in cancer cell
apoptosis and therapeutic benefits in ovarian cancer [28,29].
NF-kB/IkB signaling is another pathway that has been implicated
in drug resistance and survival in ovarian cancer [30,31]. The NF-
kB/IkB pathway is emerging as key player in tumorigenesis, invasion
and metastasis for various cancers [30,31] and is a critical step for
cancer cells to escape programmed cell death [32]. Furthermore,
resistance of cancer cells to chemotherapeutic agents has been
associated with deregulated NF-kB activation [33]. Moreover, we
have shown that inhibition of constitutively active NF-kB by
adenoviral expression of IkB induces apoptosis in prostate cancer
cells and inhibits tumor formation in SCID mice [34].
In this report, we compared a broad set of NSAIDs for their
efficacies to induce apoptosis of ovarian cancer cells. Since our
previous study demonstrated a role for mda-7/IL-24 in NSAID-
mediated cell death, we also evaluated whether apoptosis induction
by NSAIDs is due to induction of mda-7/IL-24 expression. Viral
delivery of mda-7/IL-24 is currently used in clinical trials for various
cancers [27]. Identification of drugs that are most efficient in mda-7/
IL-24 induction may provide an alternative to viral delivery for
exploiting the anti-neoplastic effects of mda-7/IL-24. We also
hypothesized that combining NSAIDs with inhibitors of the NF-kB
pathway may enhance the effects of NSAIDs against ovarian cancer.
We, therefore, tested pharmacological inhibitors of the NF-kB
pathway for their abilities to induce apoptosis in ovarian cancer cells.
Here, we demonstrate that Sulindac Sulfide and Diclofenac are the
most potent NSAIDs that induce ovarian cancer apoptosis via mda-7/
IL-24 expression and also reduce tumor growth in vivo. mda -7/IL-24
expression leads to GADD45a and c upregulation and JNK kinase
activation. Several pharmacological NF-kB inhibitors also induce
apoptosis of ovarian cancer cells and in combination with NSAIDs
potentiate the apoptotic effect of NSAIDs.
Results
NSAIDs are potent inducers of mda-7/IL-24 and
apoptosis in ovarian cancer cells
A broad panel of NSAIDs was tested for their abilities to induce
apoptosis and mda-7/IL-24 gene expression in four ovarian cancer
cell lines, SKOV-3, CAOV-3, SW626 and 36M2. The concen-
trations for all NSAIDs drugs used in this study were selected to be
comparable to achievable physiological plasma concentrations
[35–49]. Apoptosis was measured 24 hours after treatment of
SKOV-3, CAOV-3, SW626 and 36M2 ovarian cancer cells with
this set of NSAIDs, revealing that a variety of, but not all NSAIDs
induced apoptosis (Figure 1a and S1a). Consistently strong
inducers of apoptosis in all four-cell lines included Sulindac
Sulfide, Diclofenac, Ebselen and Naproxen when compared to the
solvent controls. Some NSAIDs resulted in significant induction of
apoptosis in a subset of the ovarian cancer cell lines including
Sulindac Sulfone, Acetaminophen, Aspirin and Flurbiprofen
whereas treatment with NS-398, Ibuprofen, Finasteride, Flufe-
namic Acid and Meloxicam resulted only in marginal or no
apoptosis induction (Figure 1a and S1a).
For each of the four most consistent inducers of apoptosis we
determined the lowest dose that still induces programmed cell death
of ovarian cancer cells. The concentrations of the selected NSAIDs
were tested at 2, 5 and 10 times lower concentrations than the
physiologically achievable doses used in the experiments for
Figure 1a and S1a. Apoptosis was measured in ovarian cancer cells
24 hours after treatment with different doses of the four NSAIDs.
Our results show that Sulindac Sulfide, Diclofenac and Naproxen
concentrations even at 5 times lower dose still effectively induce
apoptosis, while Ebselen can be reduced only 2-fold (Figure 1b).
Based on our previous observations in other types of cancer we
determined whether apoptosis induction by NSAIDs correlates
with mda-7/IL-24 induction. We measured mRNA expression
levels of mda-7/IL-24 mRNA in response to different NSAIDs in
SKOV-3 cells by real time PCR analysis demonstrating that mda-
7/IL-24 (maximum of 12-fold induction) expression is commonly
induced by NSAIDs that promote apoptosis in ovarian cancer cells
(Figure 1c). These results were also corroborated in two additional
ovarian cancer cell lines. In CAOV-3 and SW626 ovarian cancer
cell lines mda-7/IL-24 is also strongly induced (maximum of 77-
fold induction in CAOV-3 cells) (Figure S1b). NSAIDs that
strongly enhanced apoptosis such as Sulindac Sulfide, naproxen,
ebselen, and diclofenac (Figure 1a) significantly induced mda7/IL-
24 expression (Figure 1c), whereas NSAIDs that only marginally
induced apoptosis (Figure 1a) did not significantly enhance mda-7/
IL-24 expression except ibuprofen which induced mda-7/IL-24 but
did not induce apoptosis (Figure 1c).
We and others have shown that overexpression of mda-7/IL-24
following infection with an adenovirus carrying the mda-7/IL-24
gene induces apoptosis and inhibits cell proliferation in cancer cells
[50,51]. In order to evaluate whether induction of apoptosis in
cancer cells by NSAIDs is dependent on mda-7/IL-24 upregula-
tion, we conducted experiments with a lentivirus encoding a
siRNA against mda-7/IL-24 that was previously generated by our
group [23]. Infection of SKOV-3 cells with the mda-7/IL-24
siRNA lentivirus reduced apoptosis induced by NSAIDs by 40–
70% relative to the control lentivirus (Figure 1d), further
supporting the notion that NSAID-mediated apoptosis is at least
partially dependent on mda-7/IL-24 induction. The same results
were observed in CAOV-3 cells (data not shown).
Synergistic effects of NSAID combinations
Using the lowest dose of each NSAID that affected apoptosis of
ovarian cancer cells (Figure 1b), we systematically analyzed
apoptosis induction upon combining low doses of NSAIDs. A panel
of NSAIDs including Diclofenac, Sulindac Sulfide, Naproxen and
Ebselen were tested for their abilities to induce apoptosis alone and
in combination. SKOV-3 ovarian cancer cells were treated with
10 mM Sulindac Sulfide, 40 mM Diclofenac, 25 mM Ebselen or
40 mM Naproxen and combinations thereof. Apoptosis was
measured 24 hours after treatment revealing that the majority of
the combinations of NSAIDs tested induced apoptosis significantly
more than either of the NSAIDs alone in ovarian cancer cells
(Figure 2a). Certain combinations such as Sulindac Sulfide and
Diclofenac, Sulindac Sulfide and Naproxen and Diclofenac and
Naproxen were more effective in apoptosis induction than others
(Figure 2a). We validated these results in CAOV-3 and SW626 cell
lines (Figure S2). Isobologram analysis using combinations of
Diclofenac and Sulindac Sulfide indicates that combinations of the
drugs results in a synergistic effect (Figure 2b).
NSAID treatment reduces ovarian cancer xenograft
growth in SCID mice
To determine whether NSAIDs reduce tumor growth in vivo,
SKOV-3 ovarian cancer cells were injected subcutaneously in
SCID mice. The mice were randomly divided into 3 groups and
NSAIDs and NF-kB Inhibitors in Ovarian Cancer
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fed one of three diets through the entire experiment: AIN-93G as
the control and the AIN-93G diet supplemented with either
200ppm Sulindac Sulfide or 100ppm Diclofenac. Two months
later the animals were examined for tumor formation and tumor
weight. All mice developed tumors indicating that this particular
dose of NSAIDs did not prevent tumor formation. However, as
seen in Figure 3, Sulindac Sulfide and Diclofenac treatment
reduced the average tumor volume by 30% and 20%, respectively,
when compared to the control diet with a p-value ,0.05,
confirming its anti-tumor efficacy.
Induction of GADD45 a and c gene expression and
activation of JNK in ovarian cancer by NSAIDs
We have previously reported that induction of apoptosis by
NSAIDs is tightly linked to induction of mda-7/IL-24 expression
and consequently to GADD45 a and c upregulation in several
cancer cell lines [23]. As NSAIDs induce mda-7/IL-24 expression
in ovarian cancer cells (Figure 1c and S1c), we evaluated changes
in GADD45 a and c gene expression.
To evaluate whether regulation of GADD45 genes is involved
in NSAID-mediated apoptosis, expression of GADD45 a and c
mRNAs was measured by real time PCR in SKOV-3, CAOV-3,
and SW626 cells treated with NSAIDs. The NSAIDs with the
strongest pro-apoptotic activity including Sulindac Sulfide,
Diclofenac, Naproxen and Ebselen strongly enhanced GADD45
a and c expression, indicating that increased GADD45 a and c
expression closely correlates with pro-apoptotic activity of NSAIDs
(Figure S3a and S3b). Lentiviral expression of siRNA against mda-
7/IL-24 in ovarian cancer cells demonstrated that knockdown of
mda-7/IL-24 reduces diclofenac-induced GADD45 a and c gene
expression indicating that GADD45a and c induction is at least
partially dependent on mda-7/IL-24 expression (Figure S3c).
Since others and we had shown that JNK activation plays a role
in apoptosis induction in cancer cells and GADD45 a and c
Figure 1. Multiple NSAIDs induce apoptosis and mda-7/IL-24 gene expression in ovarian cancer cells. SKOV-3 cell line after treatment
with 5 mM Aspirin, 200 mM Ibuprofen, 1 mM Acetaminophen, 200 mM Naproxen, 200 mM NS-398, 200 mM Diclofenac, 50 mM Finasteride, 200 mM
Flufenamic acid, 40 mM Meloxicam, 50 mM Ebselen, 20 nM Flurbiprofen, 50 mM Sulindac Sulfide and 50 mM Sulindac Sulfone or DMSO as control. (A)
Apoptosis assay of ovarian cancer cells after NSAID treatment. Data means 6 s.d. of triplicate independent experiments for each treatment. (B) Dose-
dependent induction of apoptosis by NSAIDs in ovarian cancer cells. Apoptosis assay of SW626 ovarian cancer cells. Cells were treated with 50, 25, 10
and 5 mM of Sulindac Sulfide; 200, 100, 40 and 20 mM of Diclofenac; 200, 100, 40 and 20 mM of Naproxen and 50, 25, 10 and 5 mM of Ebselen or DMSO.
Apoptosis was measured 24 hours post-treatment. Data means 6 s.d. of triplicate independent experiments for each treatment. (C) Real time PCR
analysis of mda-7/IL-24 expression in SKOV-3 cells after 24 hours treatment with different NSAIDs. Each sample was normalized to hGAPDH. (D)
Apoptosis assay of CAOV-3 ovarian cancer cells after NSAID treatment or DMSO and infection with lentivirus encoding mda-7/IL-24 siRNA duplexes.
Data means 6 s.d. of triplicate independent infection for each vector at each treatment.
doi:10.1371/journal.pone.0024285.g001
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interact with the upstream kinase of JNK, MTK1 [52], we
evaluated the activation of JNK during NSAID-mediated
apoptosis. JNK kinase activity was tested in protein extracts
obtained from CAOV-3 and SKOV-3 cells treated with Sulindac
Sulfide (50 mM), Diclofenac (200 mM) or DMSO for 24 hours by
an in vitro kinase assay. Western blot analysis revealed very little
JNK activity in untreated control cells and a strong increase in
JNK activity in both cell lines upon treatment with Sulindac
Sulfide and Diclofenac (Figure 4a and 4b). Corroborating this
evidence a weak inducer of mda-7/IL-24, GADD45 a and c and
apoptosis, Flurbiprofen, demonstrated only a marginal induction
of JNK activity (data not shown). To elucidate the functional
relevance of GADD45 a and c and mda-7/IL-24 for NSAID-
mediated JNK induction and apoptosis in ovarian cancer, JNK
kinase activity was tested in protein extracts obtained from
CAOV-3 cells treated with Sulindac Sulfide and Diclofenac and
infected with lentivirus encoding siRNA against GADD45 a and
mda-7/IL-24 genes. Western blot analysis revealed JNK kinase
activation by Sulindac Sulfide and Diclofenac was markedly
dependent on GADD45 a and mda-7/IL-24 induction, since JNK
kinase activity in Sulindac Sulfide and Diclofenac treated mda-7/
IL-24-/- cells was abolished when compared to mda-7/IL-24+/+
cells (Figure 4b). In order to further characterize the effect of
NSAIDS in inducing apoptosis, the levels of PARP activation were
Figure 2. Synergistic effects of NSAID used in combinations. (A) Apoptosis assay of SKOV-3 cells after treatment with 10 mM Sulindac Sulfide,
40 mM Diclofenac, 25 mM Ebselen or 40 mM Naproxen and a combination thereof or DMSO. Apoptosis was measured 24 hours post-treatment. Data
means 6 s.d. of triplicate independent experiments for each treatment. (B) Normalised isobologram obtained by software Compusyn. CAOV-3 cells
treated with a combination of 5 mM Sulindac Sulfide and 20 mM Diclofenac shows synergistic effect.
doi:10.1371/journal.pone.0024285.g002
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measured by Western-blot, indicating that Sulindac Sulfide and
Diclofenac are strong inducers of PARP cleavage (Figure S4a).
Combinatorial treatment of pharmacological inhibitors of
the NF-kB pathway with NSAIDs induce apoptosis in
ovarian cancer cells
We investigated the biological relevance of the NF-kB pathway
in ovarian cancer cells and determined the functional consequenc-
es of its inhibition. Instead of using adenoviral delivery of the IkB
inhibitor we moved towards a more clinically relevant model and
used pharmacological inhibitors of the NF-kB pathway. Inhibitors
of the NF-kB pathway were tested for their abilities to induce
apoptosis in ovarian cancer cells. Apoptosis was measured
24 hours after treatment of SKOV-3, CAOV-3 and SW626
ovarian cancer cells with four different inhibitors of NF-kB,
5 nM 6-Amino-4-(4-phenoxyphenylethylamino) quinazoline [53],
50 mM Isohelenin [54], 50 mM IKK-2 inhibitor SC-514 [55], and
200 mM IKK inhibitor II Wedelolactone (7-Methoxy-5,11,12-
trihydroxy-coumestan) [56] or DMSO (control). 6-Amino-4-(4-
phenoxyphenylethylamino) quinazoline was an efficient inducer of
apoptosis in all three cell lines, and the IKK inhibitor II
Wedelolactone (7-Methoxy-5,11,12-trihydroxy-coumestan) in-
duced apoptosis in two of the three cell lines. Treatment with
Isohelenin or IKK-2 inhibitor SC-514 resulted only in marginal or
no apoptosis induction (Figure 5a). Additionally, Real-time PCR
analysis indicates that Wedelolactone (7-Methoxy-5,11,12-trihy-
droxy-coumestan) induces strong activation of the GADD45 a and
c gene expression (Figure S4b), and promotes JNK phosphoryla-
tion (Figure S4c) and cleavage of PARP (Figure S4a).
As for the NSAIDs we performed a dose response analysis for 6-
Amino-4-(4-phenoxyphenylethylamino) quinazoline and Wedelo-
lactone (7-Methoxy-5,11,12-trihydroxy-coumestan) to determine
the lowest dose that still induces programmed cell death of ovarian
cancer cells. Reducing the concentration of 6-Amino-4-(4-
phenoxyphenylethylamino) quinazoline from 5 nM to 1 nM still
induced apoptosis, while reduced doses of Wedelolactone resulted
in loss of apoptosis induction (Figure 5b).
To determine whether the NF-kB inhibitors 6-Amino-4-(4-
phenoxyphenylethylamino) quinazoline and Wedelolactone (7-
Methoxy-5,11,12-trihydroxy-coumestan) enhance the pro-apo-
ptotic activities of NSAIDs we combined the lowest doses of each
of the four NSAIDs, Sulindac Sulfide, Diclofenac, Ebselen, and
Naproxen with the lowest doses of the two NF-kB inhibitors that
still induce apoptosis (Figure 1b and 5b, respectively). The
NSAIDs and NF-kB inhibitors were tested for their abilities to
induce apoptosis alone and in combination. SKOV-3, CAOV-3,
and SW626 ovarian cancer cells were treated with 10 mM
Sulindac Sulfide, 40 mM Diclofenac, 25 mM Ebselen, 40 mM
Naproxen, 1 nM 6-Amino-4-(4 phenoxyphenylethylamino) qui-
nazoline and 200 mM Wedelolactone. Apoptosis was measured
24 hours after treatment revealing that combinations of NSAIDs
with the NF-kB inhibitor 6-Amino-4-(4 phenoxyphenylethyla-
mino) quinazoline significantly enhanced apoptosis in ovarian
cancer cells compared to either of the drugs alone (Figure 5c). In
contrast, Wedelolactone enhanced the pro-apoptotic effects only of
some of the NSAIDs and less efficiently in SKOV-3 cells
(Figure 5c). Isobologram analysis indicates that the combination
of 6-Amino-4-(4 phenoxyphenylethylamino) quinazoline with
Sulindac Sulfide results in a synergistic effect (Figure 5d).
Discussion
NSAIDs have emerged as potential drugs for chemoprevention
in cancer but their benefits are still in question. Some traditional
NSAIDS such as Sulindac are currently being tested in clinical
trials for various cancers. Indeed, preclinical studies provide
Figure 3. Reduction of tumor formation by NSAIDs. For each inoculation, 26106 SKOV-3 cells were injected subcutaneously into SCID mice.
The mice were randomly divided into three groups (n = 7/group) and fed one of three diets through the entire experiment: AIN-93G as the control,
the AIN-93G diet supplemented with 200 ppm Sulindac Sulfide or the AIN-93G diet supplemented with 100 ppm Diclofenac. The size of the tumors
and tumor weight were measured after 2 months. Values not sharing the same letters are statistically significant with p values at least ,0.05.
doi:10.1371/journal.pone.0024285.g003
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consistent evidence that NSAIDs can effectively inhibit tumori-
genesis in particular through inhibition of cyclooxygenase-2
(COX-2). Importantly, aspirin use has been associated with a
decreased risk of distant breast cancer recurrence and breast
cancer death [57].
Epidemiologic studies indicate inverse associations between use
of nonsteroidal anti-inflammatory drugs (NSAID) and the
incidence of ovarian cancer [5,6,7]. Several reports suggest that
certain NSAIDs induce apoptosis and cell cycle arrest in human
ovarian cancer cells but the exact molecular mechanism by which
NSAIDs induce antitumorigenic activity is not clear. Previously,
our groups described a novel pathway by which NSAIDs induce
apoptosis and growth arrest in cancer cells. We demonstrated that
induction of the pro-apoptotic cytokine MDA-7/IL-24 by
NSAIDs is crucial for programmed cell death induced by NSAIDs
[23]. However, this study did not include ovarian cancer cells.
Several reports using an adenovirus encoding the mda-7/IL-24
gene (Ad-mda-7) show its profound and selective anticancer activity
in animal models [26,27,50,58,59,60] including a report of
selectively induced cell death of ovarian cancer cells that results
in suppression of tumor growth in vivo [58]. However, transient
expression, potentially adverse immune reactions (mediated by
adenovirus) and problems with systemic delivery restrict the
generalized use of adenoviral delivery of mda-7/IL-24, particularly
when administered systemically as a non-replicating adenovirus.
In this context, our findings that NSAIDs with anti-cancer
activity induce high levels of mda-7/IL-24 in ovarian cancer cells
provide a new therapeutic strategy to enhance mda-7/IL-24 levels
on a systemic level. Indeed, we have obtained a comprehensive
overview of the consequences of a whole panel of NSAIDs on
ovarian cancer cell survival by comparing their efficacies to induce
apoptosis and mda-7/IL-24 expression. The most potent inducers
of mda-7/IL-24 gene expression include Sulindac Sulfide and
Diclofenac. Our finding corresponds with previous reports that
demonstrated that treatment of human lung tumor xenografts in
nude mice with Ad-mda-7 in addition to Sulindac reduced tumor
growth more efficiently than Ad-mda-7 [50]. Moreover, these
results corroborate our previous findings that apoptosis induction
of the pro-apoptotic cytokine mda-7/IL-24 mediates induction of
GADD45 a and c expression and JNK activity in other types of
cancer [23]. While Sulindac Sulfide and Diclofenac themselves
may not be the ideal drugs to induce mda-7/IL-24 and apoptosis in
ovarian cancer cells, and particularly Diclofenac elicits many
adverse effects in patients that limit its use in cancer patients, it
should be feasible to generate modified versions of these drugs that
are more potent in their anti-cancer activities and with reduced
Figure 4. NSAID-treatment induces JNK activation. (A) Total lysate before Immunoprecipitation. (B) Kinase assay showing induction of JNK
kinase activity by NSAIDs. Induction of JNK activation by Sulindac Sulfide and Diclofenac was analyzed in cell lysates from SKOV-3 and CAOV-3 cells
treated with 50 mM Sulindac Sulfide, 100 mM Diclofenac or DMSO using the SAPK/JNK assay Kit (Cell Signaling). (C) Western Blot analysis using
anti-phospho JNK antibody of cell lysates from CAOV-3 cells treated with 50 mM Sulindac Sulfide, 100 mM Diclofenac or DMSO and infection with
lentivirus encoding mda-7/IL-24 siRNA, GADD45a and GFP duplexes.
doi:10.1371/journal.pone.0024285.g004
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adverse and off-target effects. Indeed a modified version of
Sulindac has recently been reported to be more active against
cancer cells without inhibiting COX 1 and 2 [61].
Diclofenac has previously been shown to induce apoptosis in
colon and squamous cell carcinoma and to inhibit pancreatic
tumor growth [62,63]. However, there are no reports about its use
in ovarian cancer. Here, we demonstrate that Diclofenac as well as
Sulindac Sulfide induce apoptosis and inhibit tumor growth of
ovarian cancer. These compelling data reinforce the notion of the
potential benefits of NSAID treatment for ovarian cancer.
We also identified Naproxen and Ebselen as moderate inducers
of apoptosis and mda-7/IL-24 expression in ovarian cancer cells.
While Naproxen helps to prevent urinary bladder and colon
carcinogenesis [64], Ebselen has been shown to reduce cisplatin
treatment toxicity in rat ovarian cancer models, enhancing anti-
tumor activity and improving mortality, morbidity and outcome
[65]. As mentioned before, we have reported that induction of
mda-7/IL-24 by structurally different NSAIDs is crucial for
apoptosis induction of breast, prostate, renal and stomach cancer
cells [23]. However, in this previous study, Naproxen and Ebselen
had only marginal effects on apoptosis induction. In this report, we
observed different drug activities for Naproxen and Ebselen.
Ebselen and Naproxen induced apoptosis and mda-7/IL-24
expression in ovarian cancer cells and also synergized with the
more potent NSAIDs, Diclofenac and Sulindac Sulfide, suggesting
potential clinical utility in ovarian cancer therapy.
We have previously shown that inhibition of NF-kB in cancer
cells increases apoptosis without promoting mda-7/IL-24 produc-
tion [23]. One of the major transcriptional circuits implicated in
inflammation is the NF-kB/IkB pathway [66]. Furthermore, NF-
Figure 5. Combinatorial treatment of ovarian cancer cells with NSAIDs and NF-kB inhibitors. (A) Pharmacological NF-kB inhibitors induce
apoptosis in ovarian cancer cells. SW626, CAOV-3, and SKOV-3 cells after treatment with 5 nM 6-Amino-4-(4-phenoxyphenylethylamino) quinazoline
(6-amino), 50 mM Isohelenin, 50 mM IKK-2 inhibitor SC-514, and 200 mM IKK inhibitor II Wedelolactone (7-Methoxy-5,11,12-trihydroxy-coumestan) or
DMSO as control. Data means 6 s.d. of triplicate independent experiments for each treatment. (B) Dose-dependent induction of apoptosis by NF-kB
inhibitors in ovarian cancer cells. Apoptosis assay of SKOV-3 ovarian cancer cells. Cells were treated with 5, 2.5, 1 and 0.5 nM of 6-Amino-4-(4-
phenoxyphenylethylamino) quinazoline (6-amino) 50, 25, 10 and 5 mM of Isohelenin, 50, 25, 10 and 5 mM of IKK inhibitor II Wedelolactone (7-
Methoxy-5,11,12-trihydroxy-coumestan) (Wedelolactone), 50, 25, 10 and 5 mM of IKK-2 inhibitor SC-514 or DMSO. Apoptosis was measured 24 hours
post-treatment. Data means 6 s.d. of triplicate independent experiments for each treatment. (C) Apoptosis in ovarian cancer cells after NSAID
treatment in combination with NF-kB inhibitors. SW626, CAOV-3, and SKOV-3 cells after treatment with 10 mM Sulindac Sulfide, 40 mM Diclofenac,
25 mM Ebselen, 40 mM Naproxen, 1 nM 6-Amino-4-(4 phenoxyphenylethylamino) quinazoline (6-amino), and 200 mM IKK inhibitor II Wedelolactone
and a combination thereof. Apoptosis was measured 24 hours after treatment. Data means 6 s.d. of triplicate independent experiments for each
treatment. (D) Normalised isobologram obtained by software Compusyn. CAOV-3 cells treated with a combination of 10 mM Sulindac Sulfide and
2.5 nM 6-amino shows synergistic effect.
doi:10.1371/journal.pone.0024285.g005
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kB has been implicated in cancer cell survival and escape from
programmed cell death and is activated by chemotherapeutic
agents in cancer cells [30,31,33]. Mutations in different genes of
the NF-kB pathway and constitutively active NF-kB are frequently
observed in various types of cancer [33]. Indeed, ovarian cancer
cells frequently contain activated NF-kB prior to therapy and are,
therefore, expected to be resistant to chemotherapy a priori. On the
other hand, we have demonstrated that inhibition of activated NF-
kB in cancer cells induces apoptosis without the addition of a
chemotherapeutic agent indicating the central role of NF-kB in
cell survival of many cancer cells. These findings also suggest the
possibility of enhancing therapeutic outcomes by combining NF-
kB inhibitors with chemotherapy or other drugs such as NSAIDs.
At high concentrations, NSAIDs have been shown to inhibit the
TNF-mediated activation of NF-kB [67]. However, we have
previously shown that at achievable plasma concentrations,
NSAIDs Sulindac Sulfide has no effect on the NF-kB signaling
pathway [23]. Indeed here we demonstrate that NF-kB inhibitors
strongly induce apoptosis in ovarian cancer cells. Importantly, NF-
kB inhibitors markedly enhanced the efficacy of NSAIDs to induce
apoptosis, corroborating our hypothesis that these combinatorial
regimens can be utilized even though animal model studies are still
necessary to prove its efficacy in vivo.
In summary, our results strongly support the hypothesis that
drug treatment regimens that lead to enhanced mda-7/IL-24
expression in cancer cells and block NF-kB may have significant
efficacy against ovarian cancer. These results also provide a
rationale to screen for additional small molecules, natural
compounds or even chemically modified NSAIDs, which selec-
tively and efficiently induce mda-7/IL-24 expression in order to
obtain more potent anti-cancer drugs.
Materials and Methods
Cell cultures
The ovarian cancer cell lines SKOV-3, CAOV-3, and SW626
were obtained from American Type Culture Collection (Rockville,
MD). 36M2 cells were kindly provided by Dr. Dimitrios Spentzos,
Beth Israel Deaconess Medical Center. SKOV-3 were grown in
McCoy’ 5a modified medium (Life Technologies, Carlsbad, CA),
SW626 were grown in L-15 medium; and CAOV-3 and 36M2
were grown in DMEM (Life Technologies, Carlsbad, CA). The
medium was supplemented with 10% fetal bovine serum (FBS), 50
units of penicillin/mL, and 50 mg streptomycin/mL (all from
Life Technologies). The cells were maintained in a 5% CO2-
humidified incubator at 37uC.
Reagents
Sulindac Sulfide, Sulindac Sulfone, Ibuprofen, Aspirin, Acet-
aminophen, and Naproxen were obtained from Sigma-Aldrich (St.
Louis, MO). Meloxicam, Diclofenac, Finasteride, and Flufenamic
acid were obtained from LKT Laboratories (St. Paul, MN). NS-
398, Ebselen, and Flurbiprofen were purchased from Calbiochem
(San Diego, CA). The drugs were dissolved in DMSO or ethanol.
Cancer cells were treated in their particular medium for 24 hours.
The concentrations of the different NSAIDs were chosen to be
physiologically achievable doses. The final concentrations for each
compound were as follows: 5 mM Aspirin, 200 mM Ibuprofen,
1 mM Acetaminophen, 200 mM Naproxen, 200 mM NS-398,
200 mM Diclofenac, 50 mM Finasteride, 200 mM Flufenamic acid,
40 mM Meloxicam, 50 mM Ebselen, 20 nM Flurbiprofen, 50 mM
Sulindac Sulfide and 50 mM Sulindac Sulfone. For the controls,
cells were treated with an equal amount of DMSO or ethanol,
which was ,0.1% of the final concentration.
NF-kB inhibitors: 5 nM 6-Amino-4-(4-phenoxyphenylethyla-
mino) quinazoline, 50 mM Isohelenin, 50 mM IKK-2 inhibitor SC-
514, and 200 mM IKK inhibitor II Wedelolactone (7-Methoxy-
5,11,12-trihydroxy-coumestan) were purchased from Calbiochem
(San Diego, CA).
Real-time PCR
Total RNA was harvested using QIAshredder (Qiagen, Valencia,
CA) and RNeasy Mini kit (Qiagen). Real-time PCR was performed
as described [23]. The full description of the method is described in
Methods S1. The sequences of the primers are as follows: mda-7/IL-
24, sense 59-CAAAGCCTGTGGACTTTAGCC-39; antisense 59-
GAATAGCAGAAACCGCCTGTG- 39; hGAPDH, sense 59-
CAAAGTTGTCATGGATGACC-39; antisense 59-CCATGGA-
GAAGGCTGGGG-39. GADD45a, sense 59-GCCTGTGAGT-
GAGTGCAGAA- 39; antisense 59-ATCTCTGTCGTCGTC-
CTCGT-39; GADD45c, sense 59-CTGCATGAGTTGCTGC-
TGTC- 39; antisense 59-TTCGAAATGAGGATGCAGTG –39.
Kinase assay
JNK kinase activity was measured by using the SAPK/JNK
assay kit (Cell Signaling Technology) according to the manufac-
turer’ protocol. Briefly, CAOV-3 and 36M2 cells were treated
with Sulindac Sulfide, Diclofenac or DMSO for 16 hours. Whole-
cell lysates of treated and control cells were prepared in lysis buffer
[20 mmol/L Tris (pH 7.4), 150 mmol/L NaCl, 1 mmol/L
EDTA, 1 mmol/L EGTA, 1% Triton X-100, 2.5 mmol/L
sodium PPi, 1 mmol/L bGlycerophosphate, 1 mmol/L Na3VO4,
1 m g/mL leupeptin, and 1 mmol/L phenylmethylsulfonyl fluo-
ride]. 500 mg of the clarified lysate were immunoprecipitated using
2 mg agarose-conjugated anti-c-jun monoclonal antibody (Cell
Signaling, Beverly MA) overnight at 4uC. The beads were washed
twice with lysis buffer and twice with kinase buffer (25 mM Tris
(pH 7.5), 5 mM b-Glycerophosphate, 2 mM DTT, 0.11 mM
Na3VO4, 10 mM MgCl2) and subjected to the kinase assays. The
beads were suspended in 50 ml kinase buffer supplemented with
200 mM ATP and incubated for 30 minutes at 30uC. The
reactions were terminated by adding 25 ml 3X SDS sample buffer
and proteins were resolved by SDS-10% PAGE and probed with
phospho-c-jun antibody (Cell Signalling).
Western-blot
Western-blot were performed as described in supplementary
information by using antibodies against total SAPK/JNK (New
England Biolabs), phospho JNK (Cell Signaling), mda-7/IL-24
(kindly provided by Paul B. Fisher, Virginia Commonwealth
University, School of Medicine, Richmond, VA), PARP and
GAPDH (Santa Cruz Biotechnology).
Apoptotic assays
Apoptosis was assayed by using the Apoptotic Cell Death
Detection ELISA (Roche) according to the manufacturer’ protocol.
Significant statistical difference of control samples against samples
treated with NSAIDs was determined by Student’ t-test.
Isobologram
The isobologram was calculated using Calcusyn software
(Biosoft). The drugs were applied across a range of concentrations
and cell proliferation was evaluated using the MTT assay at each
dosage. Data from cell proliferation was expressed as the fraction
of cells inhibited by drug treatments compared with untreated
cells. Interaction between pairs of drugs was determined using
the Calcusyn software, which generated the isolobogram. The
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isobologram is a graphical representation of the interaction
between two drugs and is formed by plotting the individual drug
doses required to achieve a single agent effect on their respective x
and y axes, a line connecting the two points is drawn and the
concentrations of the two drugs used in combination to achieve the
same effect are plotted on the isobologram. Combination data
points that fall on the line represent an additive interaction,
whereas points above or below represent antagonism or synergy,
respectively.
Lentivirus constructs
The lentiviruses encoding siRNA against the three GADD45
family members have been previously described [34]. The
LVsiRNA GFP construct (control) was kindly donated by Dr.
Oded Singer (Salk Institute for Biological Studies, San Diego, CA).
The lentivirus encoding siRNA against mda-7/IL-24 gene was
cloned using Advantage 2 PCR kit (Clontech, Mountain View,
CA), and the virus was generated by using a previously described
methodology [34]. The following siRNA oligonucleotide for mda-
7/IL-24 was used: 59CTGTCTAGACAAAAACTTTGTTCT-
CATCGTGTCATCTCTTGAATGACACGATGAGAACAAA-
GGGGGATCTGTGGTCTCATACA-39.
Animal experiment
Severe combined immunodeficient (SCID)-beige mice were
purchased from Taconic (Germantown, NY) and housed in a
pathogen-free environment. The animals were randomly divided
into 3 groups (n = 7 per group). 8-week-old female SCID-beige
mice were fed with one of the experimental diets supplemented
with 200 ppm of Sulindac Sulfide, 100 ppm of Diclofenac or
control solvents for 2 weeks. Immediately before implantation,
SKOV-3 cells were trypsinized and resuspended in MEM with
10% fetal bovine serum. Cell viability was determined by trypan
blue exclusion and a single cell suspension with .90% viability
was used for implantation. SKOV-3 cells (26106 cells in 50 ml)
were carefully injected subcutaneously as described previously
[23,34] and animals continued on experimental diets. Tumor size
(volume) was measured every 5 days, starting at day 35 after
implantation. The experiment was finished when the average
tumor weight in the control animals reached 2–5% of the body
weight. The diets were prepared by Research Diets, Inc. (New
Brunswick, NJ). Body weight and food intake were measured
weekly. All procedures with animals were reviewed and approved
by the Institutional Animal Care and Use Committee at the Beth
Israel Deaconess Medical Center according to NIH guidelines.
Supporting Information
Figure S1 Multiple NSAIDs induce apoptosis and mda-
7/IL-24 gene expression in ovarian cancer cells. CAOV-3
and SW626 ovarian cancer cell lines after treatment with 5 mM
Aspirin, 200 mM Ibuprofen, 1 mM Acetaminophen, 200 mM
Naproxen, 200 mM NS-398, 200 mM Diclofenac, 50 mM Finaste-
ride, 200 mM Flufenamic acid, 40 mM Meloxicam, 50 mM
Ebselen, 20 nM Flurbiprofen, 50 mM Sulindac Sulfide and
50 mM Sulindac Sulfone or DMSO as control. (A) Apoptosis
assay of ovarian cancer cells after NSAID treatment. Data means
6 s.d. of triplicate independent experiments for each treatment.
(B) Real time PCR analysis of mda-7/IL-24 expression in SKOV-3
cells after 24 hours treatment with different NSAIDs. Each sample
was normalized to hGAPDH. (C) NSAIDs mediated induction of
mda-7/IL-24. Western-blot analysis using antibody against mda-7/
IL-24 (kindly provided by Dr. Paul B. Fisher, Virginia Common-
wealth University, School of Medicine) shows that treatment with
50 mM Sulindac Sulfide induces mda-7/IL-24 expression in a cell
line with silenced GFP control gene, while cells with silenced mda-
7/IL-24 and treated with 50 mM Sulindac Sulfide shows
abrogation of its induced expression mediated by NSAIDs.
(TIF)
Figure S2 Synergistic effects of NSAID used in combi-
nations. (A) Apoptosis assay of CAOV-3 and SW626 cells after
treatment with 10 mM Sulindac Sulfide, 40 mM Diclofenac,
25 mM Ebselen or 40 mM Naproxen and a combination thereof
or DMSO. Apoptosis was measured 24 hours post-treatment.
Data means 6 s.d. of triplicate independent experiments for each
treatment.
(TIF)
Figure S3 NSAIDS treatment of ovarian cancer cells
induces GADD45 family gene expression. Real time PCR
analysis of GADD45a (A) and GADD45c (B) expression after
NSAIDS treatment with 5 mM Aspirin, 200 mM Ibuprofen,
1 mM Acetaminophen, 200 mM Naproxen, 200 mM NS-398,
200 mM Diclofenac, 50 mM Finasteride, 200 mM Flufenamic acid,
40 mM Meloxican, 50 mM Ebselen, 20 nM Flurbiprofen, 50 mM
Sulindac Sulfide and 50 mM Sulindac Sulfone or DMSO as
control. Total RNA was collected from SKOV-3, CAOV-3 and
SW626 cells 24 hours after treatment. Normalization of each
sample was carried out by measuring the amount of hGAPDH
cDNA. (C) Real time PCR analysis of GADD45 a and c
expression after treatment with 200 mM Diclofenac and infection
with lentivirus encoding siRNA against mda-7/IL-24 or GFP
genes. Total RNA was collected from SKOV-3 cell lines after
24 hours after treatment.
(TIF)
Figure S4 NSAIDs and NF-kB inhibitor activities in
ovarian cancer cells. (A) NSAIDs and NF-kB inhibitors induce
PARP activation. Western Blot analysis using anti PARP antibody
(Santa Cruz) of cell lysates from CAOV-3 cells treated with 50 mM
Sulindac Sulfide, 100 mM Diclofenac, 200 mM IKK inhibitor II
Wedelolactone (7-Methoxy-5,11,12-trihydroxy-coumestan) or
DMSO. (B) Real-time PCR analysis of CAOV-3 cells treated
with 200 mM IKK inhibitor II Wedelolactone (7-Methoxy-
5,11,12-trihydroxy-coumestan) or DMSO shows induced expres-
sion of GADD45 a and c genes, (C) while western Blot analysis
using anti-phospho JNK antibody of cell lysates from CAOV-3
cells treated with 200 mM IKK inhibitor II Wedelolactone (7-
Methoxy-5,11,12-trihydroxy-coumestan) or DMSO shows activa-
tion of JNK.
(TIF)
Methods S1 Description of Real Time methodology.
(DOCX)
Acknowledgments
We are grateful to Dr. Inder M. Verma and Dr. Oded Singer for help with
the generation of lentiviruses.
Author Contributions
Conceived and designed the experiments: LFZ RET AC JZ DS PBF TAL.
Performed the experiments: LFZ RET RGC AC JC MB FMS YW XG LL
JZ. Analyzed the data: LFZ RET RGC AC JC MB FMS YW XG LL JZ
DS PBF TAL. Contributed reagents/materials/analysis tools: RGC DS
PBF. Wrote the paper: LFZ RET DS PBF TAL.
NSAIDs and NF-kB Inhibitors in Ovarian Cancer
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24285
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008.
CA Cancer J Clin 58: 71–96.
2. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003) Survival and
prognostic factors in patients with ovarian cancer. Obstet Gynecol 101:
885–891.
3. Berkel H, Holcombe RF, Middlebrooks M, Kannan K (1996) Nonsteroidal
antiinflammatory drugs and colorectal cancer. Epidemiol Rev 18: 205–217.
4. Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, et al. (1999) The
relationship of nonsteroidal anti-inflammatory drug use to the risk of breast
cancer. Prev Med 29: 72–76.
5. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, et al. (1998)
Over-the-counter analgesics and risk of ovarian cancer. Lancet 351: 104–107.
6. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM (2008)
Inverse association of NSAID use and ovarian cancer in relation to oral
contraceptive use and parity. Br J Cancer 98: 1781–1783.
7. Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, et al.
(2002) Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian
carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive
agents. Clin Cancer Res 8: 202–209.
8. Lacey JV, Jr., Sherman ME, Hartge P, Schatzkin A, Schairer C (2004)
Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer
108: 281–286.
9. Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE (2009) Use
of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2
large prospective cohorts. Am J Epidemiol 169: 1378–1387.
10. Vane JR, Botting RM (1998) Mechanism of action of antiinflammatory drugs.
Int J Tissue React 20: 3–15.
11. Dore M, Cote LC, Mitchell A, Sirois J (1998) Expression of prostaglandin G/H
synthase type 1, but not type 2, in human ovarian adenocarcinomas. J Histochem
Cytochem 46: 77–84.
12. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, et al. (2003)
Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor
production in ovarian cancer. Cancer Res 63: 906–911.
13. Klimp AH, Hollema H, Kempinga C, van der Zee AG, de Vries EG, et al.
(2001) Expression of cyclooxygenase-2 and inducible nitric oxide synthase in
human ovarian tumors and tumor-associated macrophages. Cancer Res 61:
7305–7309.
14. Matsumoto Y, Ishiko O, Deguchi M, Nakagawa E, Ogita S (2001)
Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian
neoplasms. Int J Mol Med 8: 31–36.
15. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, et al.
(1995) Expression of vascular endothelial growth factor and its receptors flt and
KDR in ovarian carcinoma. J Natl Cancer Inst 87: 506–516.
16. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, et al. (1996) Strong
expression of vascular permeability factor (vascular endothelial growth factor)
and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 74:
1105–1115.
17. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, et al. (1997)
Vascular endothelial growth factor expression in early stage ovarian carcinoma.
Cancer 80: 98–106.
18. Urick ME, Giles JR, Johnson PA (2008) VEGF expression and the effect of
NSAIDs on ascites cell proliferation in the hen model of ovarian cancer. Gynecol
Oncol 110: 418–424.
19. Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular endothelial growth factor
in ovarian cancer: inhibition of ascites formation by immunoneutralization.
Am J Pathol 153: 1249–1256.
20. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, et al. (1995)
Pathogenesis of ascites tumor growth: vascular permeability factor, vascular
hyperpermeability, and ascites fluid accumulation. Cancer Res 55: 360–368.
21. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, et al. (2003) Vascular
endothelial growth factor-trap decreases tumor burden, inhibits ascites, and
causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer
Res 9: 5721–5728.
22. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB (1995) Subtraction
hybridization identifies a novel melanoma differentiation associated gene,
mda-7, modulated during human melanoma differentiation, growth and
progression. Oncogene 11: 2477–2486.
23. Zerbini LF, Czibere A, Wang Y, Correa RG, Otu H, et al. (2006) A novel
pathway involving melanoma differentiation associated gene-7/interleukin-24
mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth
arrest of cancer cells. Cancer Res 66: 11922–11931.
24. Vairapandi M, Balliet AG, Hoffman B, Liebermann DA (2002) GADD45b and
GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell
cycle checkpoints induced by genotoxic stress. J Cell Physiol 192: 327–338.
25. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, et al.
(2001) Genomic structure, chromosomal localization and expression profile of a
novel melanoma differentiation associated (mda-7) gene with cancer specific
growth suppressing and apoptosis inducing properties. Oncogene 20:
7051–7063.
26. Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, et al. (2009) Historical
perspective and recent insights into our understanding of the molecular and
biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther
8: 391–400.
27. Dash R, Bhutia SK, Azab B, Su ZZ, Quinn BA, et al. (2010) mda-7/IL-24: a
unique member of the IL-10 gene family promoting cancer-targeted toxicity.
Cytokine Growth Factor Rev 21: 381–391.
28. Emdad L, Sarkar D, Lebedeva IV, Su ZZ, Gupta P, et al. (2006) Ionizing
radiation enhances adenoviral vector expressing mda-7/IL-24-mediated apop-
tosis in human ovarian cancer. J Cell Physiol 208: 298–306.
29. Yacoub A, Liu R, Park MA, Hamed HA, Dash R, et al. (2010) Cisplatin
enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-
dependent melanoma differentiation-associated gene-7/interleukin-24-induced
killing in ovarian carcinoma cells. Mol Pharmacol 77: 298–310.
30. Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev
Immunol 2: 725–734.
31. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from
innocent bystander to major culprit. Nat Rev Cancer 2: 301–310.
32. Zerbini LF, Wang Y, Cho JY, Libermann TA (2003) Constitutive activation of
nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated
interleukin 6 expression in prostate cancer. Cancer Res 63: 2206–2215.
33. Baldwin AS (2001) Control of oncogenesis and cancer therapy resistance by the
transcription factor NF-kappaB. J Clin Invest 107: 241–246.
34. Zerbini LF, Wang Y, Czibere A, Correa RG, Cho JY, et al. (2004) NF-kappa B-
mediated repression of growth arrest- and DNA-damage-inducible proteins
45alpha and gamma is essential for cancer cell survival. Proc Natl Acad Sci U S A
101: 13618–13623.
35. Carlin JR, Hoglund P, Eriksson LO, Christofalo P, Gregoire SL, et al. (1992)
Disposition and pharmacokinetics of [14C]finasteride after oral administration
in humans. Drug Metab Dispos 20: 148–155.
36. Davies NM, McLachlan AJ, Day RO, Williams KM (2000) Clinical
pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-
oxygenase-2 inhibitor. Clin Pharmacokinet 38: 225–242.
37. Kennedy JM, van Rij AM (2006) Drug absorption from the small intestine in
immediate postoperative patients. Br J Anaesth 97: 171–180.
38. Liu XH, Yao S, Kirschenbaum A, Levine AC (1998) NS398, a selective
cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2
expression in LNCaP cells. Cancer Res 58: 4245–4249.
39. Su SF, Chou CH, Kung CF, Huang JD (2003) In vitro and in vivo comparison
of two diclofenac sodium sustained release oral formulations. Int J Pharm 260:
39–46.
40. Terlinden R, Feige M, Romer A (1988) Determination of the two major
metabolites of ebselen in human plasma by high-performance liquid chroma-
tography. J Chromatogr 430: 438–442.
41. Khosravan R, Wu JT, Joseph-Ridge N, Vernillet L (2006) Pharmacokinetic
interactions of concomitant administration of febuxostat and NSAIDs. J Clin
Pharmacol 46: 855–866.
42. Lentjes EG, van Ginneken CA (1987) Pharmacokinetics of flufenamic acid in
man. Int J Clin Pharmacol Ther Toxicol 25: 185–187.
43. Lockwood GF, Albert KS, Gillespie WR, Bole GG, Harkcom TM, et al. (1983)
Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships.
Clin Pharmacol Ther 34: 97–103.
44. Ravis WR, Diskin CJ, Campagna KD, Clark CR, McMillian CL (1993)
Pharmacokinetics and dialyzability of sulindac and metabolites in patients with
end-stage renal failure. J Clin Pharmacol 33: 527–534.
45. Ray GF, Lanman RC, Fu CJ, Paranka NS, Pamukcu R, et al. (1995)
Determination of FGN-1 (an active metabolite of sulindac) in human plasma,
urine, and feces by HPLC. J Pharm Biomed Anal 14: 213–220.
46. Roberts DG, Gerber JG, Barnes JS, Zerbe GO, Nies AS (1985) Sulindac is not
renal sparing in man. Clin Pharmacol Ther 38: 258–265.
47. Skjodt NM, Davies NM (1999) Clinical pharmacokinetics and pharmacody-
namics of bromfenac. Clin Pharmacokinet 36: 399–408.
48. Swanson BN, Boppana VK, Vlasses PH, Holmes GI, Monsell K, et al. (1982)
Sulindac disposition when given once and twice daily. Clin Pharmacol Ther 32:
397–403.
49. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin
and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396: 77–80.
50. Oida Y, Gopalan B, Miyahara R, Inoue S, Branch CD, et al. (2005) Sulindac
enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in
human lung cancer. Mol Cancer Ther 4: 291–304.
51. Lebedeva IV, Su ZZ, Sarkar D, Gopalkrishnan RV, Waxman S, et al. (2005)
Induction of reactive oxygen species renders mutant and wild-type K-ras
pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. Onco-
gene 24: 585–596.
52. Mita H, Tsutsui J, Takekawa M, Witten EA, Saito H (2002) Regulation of
MTK1/MEKK4 kinase activity by its N-terminal autoinhibitory domain and
GADD45 binding. Mol Cell Biol 22: 4544–4555.
53. Tobe M, Isobe Y, Tomizawa H, Nagasaki T, Takahashi H, et al. (2003) A novel
structural class of potent inhibitors of NF-kappa B activation: structure-activity
relationships and biological effects of 6-aminoquinazoline derivatives. Bioorganic
& medicinal chemistry 11: 3869–3878.
54. Lyss G, Knorre A, Schmidt TJ, Pahl HL, Merfort I (1998) The anti-
inflammatory sesquiterpene lactone helenalin inhibits the transcription factor
NSAIDs and NF-kB Inhibitors in Ovarian Cancer
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24285
NF-kappaB by directly targeting p65. The Journal of biological chemistry 273:
33508–33516.
55. Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, et al. (2003) A
selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in
interleukin-1 beta-stimulated synovial fibroblasts. The Journal of biological
chemistry 278: 32861–32871.
56. Kobori M, Yang Z, Gong D, Heissmeyer V, Zhu H, et al. (2004) Wedelolactone
suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK
complex. Cell death and differentiation 11: 123–130.
57. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, et al. (2010) Aspirin
intake and survival after breast cancer. J Clin Oncol 28: 1467–1472.
58. Gopalan B, Shanker M, Chada S, Ramesh R (2007) MDA-7/IL-24 suppresses
human ovarian carcinoma growth in vitro and in vivo. Mol Cancer 6: 11.
59. Su ZZ, Madireddi MT, Lin JJ, Young CS, Kitada S, et al. (1998) The cancer
growth suppressor gene mda-7 selectively induces apoptosis in human breast
cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci U S A
95: 14400–14405.
60. Wang CJ, Zhang H, Chen K, Zheng JW, Xiao CW, et al. (2010) Ad.mda-7 (IL-
24) selectively induces apoptosis in hepatocellular carcinoma cell lines,
suppresses metastasis, and enhances the effect of doxorubicin on xenograft
tumors. Oncol Res 18: 561–574.
61. Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, et al. (2010) Phospho-
sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon
cancer prevention in mice. Gastroenterology 139: 1320–1332.
62. Sanyal SN, Kaur J (2010) Induction of apoptosis as a potential chemopreventive
effect of dual cycloxygenase inhibitor, diclofenac, in early colon carcinogenesis.
J Environ Pathol Toxicol Oncol 29: 41–53.
63. Fecker LF, Stockfleth E, Braun FK, Rodust PM, Schwarz C, et al. (2010)
Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment
with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP.
J Invest Dermatol 130: 2098–2109.
64. Steele VE, Rao CV, Zhang Y, Patlolla J, Boring D, et al. (2009)
Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent
models of colon, urinary bladder, and mammary cancers. Cancer Prev Res
(Phila Pa) 2: 951–956.
65. Lynch ED, Gu R, Pierce C, Kil J (2005) Combined oral delivery of ebselen and
allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer
models while enhancing anti-tumor activity. Anticancer Drugs 16: 569–579.
66. Karin M, Delhase M (2000) The I kappa B kinase (IKK) and NF-kappa B: key
elements of proinflammatory signalling. Semin Immunol 12: 85–98.
67. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB (2004) Nonsteroidal anti-
inflammatory agents differ in their ability to suppress NF-kappaB activation,
inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of
tumor cell proliferation. Oncogene 23: 9247–9258.
NSAIDs and NF-kB Inhibitors in Ovarian Cancer
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24285
